The IL-33 gene is related to increased susceptibility to systemic sclerosis

Rheumatology International

Volumn 36, Issue 4, 2016, Pages 579-584

  Koca, Suleyman Serdar ^a   Pehlivan, Yavuz ^b   Kara, Murat ^c   Alibaz Oner, Fatma ^d   Oztuzcu, Serdar ^e   Yilmaz, Neslihan ^f   Cetin, Gozde Yildirim ^g   Kisacik, Bunyamin ^e   Ozgen, Metin ^h   Pamuk, Omer Nuri ⁱ   Direskeneli, Haner ^d   Sayarlioglu, Mehmet ^h   Onat, Ahmet Mesut ^e  

^a FIRAT UNIVERSITY   (Turkey)

^b ULUDAG UNIVERSITY   (Turkey)

^c MUGLA SITKI KOCMAN UNIVERSITY   (Turkey)

^d MARMARA UNIVERSITY   (Turkey)

^e GAZIANTEP UNIVERSITY   (Turkey)

^f FLORENCE NIGHTINGALE HOSPITAL   (Turkey)

^g KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

^h ONDOKUZ MAYIS UNIVERSITY   (Turkey)

ⁱ TRAKYA UNIVERSITY   (Turkey)

Author keywords

Genetic; IL 33 gene polymorphism; Systemic sclerosis

Indexed keywords

GENOMIC DNA; INTERLEUKIN 33; IL33 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DNA ISOLATION; FEMALE; FINGER ULCER; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC SCLEROSIS; TURKISH CITIZEN; CASE CONTROL STUDY; CLINICAL TRIAL; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; HOMOZYGOTE; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PHENOTYPE; RISK FACTOR; SCLERODERMA, SYSTEMIC; TURKEY;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INTERLEUKIN-33; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; SCLERODERMA, SYSTEMIC; TURKEY;

EID: 84953372296     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-015-3417-8     Document Type: Article

References (35)

1. Greenblatt MB, Aliprantis AO (2013) The immune pathogenesis of scleroderma: context is everything. Curr Rheumatol Rep 15:297
2. Fuschiotti P (2011) Role of IL-13 in systemic sclerosis. Cytokine 56:544–549
3. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479–490
4. Lécart S, Lecointe N, Subramaniam A, Alkan S, Ni D, Chen R, Boulay V, Pène J, Kuroiwa K, Tominaga S, Yssel H (2002) Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. Eur J Immunol 32:2979–2987
5. Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S (2010) IL-33 and IL-33 receptors in host defense and diseases. Allergol Int 59:143–160
6. Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY (2007) IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 37:2779–2786
7. Wynn TA (2004) Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 4(8):583–594
8. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24(2):328–332
9. Needleman BW, Wigley FM, Stair RW (1992) Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 35:67–72
10. Mavalia C, Scaletti C, Romagnani P, Carossino AM, Pignone A, Emmi L, Pupilli C, Pizzolo G, Maggi E, Romagnani S (1997) Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 151(6):1751–1758
11. Rankin AL, Mumm JB, Murphy E, Turner S, Yu N, McClanahan TK, Bourne PA, Pierce RH, Kastelein R, Pflanz S (2010) IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol 184(3):1526–1535
12. Manetti M, Guiducci S, Ceccarelli C, Romano E, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, Matucci-Cerinic M (2011) Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement. Ann Rheum Dis 70(10):1876–1878
13. Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S (2011) Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol 30(6):825–830
14. Terras S, Opitz E, Moritz RK, Höxtermann S, Gambichler T, Kreuter A (2013) Increased serum IL-33 levels may indicate vascular involvement in systemic sclerosis. Ann Rheum Dis 72(1):144–145
15. Englert H, Small-McMahon J, Chambers P, O’Connor H, Davis K, Manolios N, White R, Dracos G, Brooks P (1999) Familial risk estimation in systemic sclerosis. Aust N Z J Med 29(1):36–41
16. Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD (2001) Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 44(6):1359–1362
17. Sakashita M, Yoshimoto T, Hirota T, Harada M, Okubo K, Osawa Y, Fujieda S, Nakamura Y, Yasuda K, Nakanishi K, Tamari M (2008) Association of serum interleukin-33 level and the interleukin-33 genetic variant with Japanese cedar pollinosis. Clin Exp Allergy 38:1875–1881
18. Chapuis J, Hot D, Hansmannel F, Kerdraon O, Ferreira S, Hubans C et al (2009) Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer’s disease. Mol Psychiatry 14:1004–1016
19. Li C, Mu R, Guo J, Wu X, Tu X, Liu X, Hu F, Guo S, Zhu J, Xu H, Li Z (2014) Genetic variant in IL33 is associated with susceptibility to rheumatoid arthritis. Arthritis Res Ther 16(2):R105
20. Fan D, Ding N, Yang T, Wu S, Liu S, Liu L, Hu Y, Duan Z, Xia G, Xu S, Xu J, Ding C, Pan F (2014) Single nucleotide polymorphisms of the interleukin-33 (IL-33) gene are associated with ankylosing spondylitis in Chinese individuals: a case–control pilot study. Scand J Rheumatol 43(5):374–379
21. Koca SS, Kara M, Deniz F, Ozgen M, Demir CF, Ilhan N, Isik A (2015) Serum IL-33 level and IL-33 gene polymorphisms in Behçet’s disease. Rheumatol Int 35(3):471–477
22. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65(11):2737–2747
23. Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D’Angelo S et al (2001) European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60(6):592–598
24. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26(10):2159–2167
25. Shi YY, He L (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15(2):97–98
26. Krieg T, Abraham D, Lafyatis R (2007) Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther 9(Suppl 2):S4
27. Postlethwaite AE, Shigemitsu H, Kanangat S (2004) Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 16:733–738
28. Van de Veerdonk FL, Netea MG (2013) New insights in the immunobiology of IL-1 family members. Front Immunol 4:167
29. Manetti M, Ibba-Manneschi L, Liakouli V, Guiducci S, Milia AF, Benelli G et al (2010) The IL1-like cytokine IL-33 and its receptor ST2 are abnormally espresse in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis 69:598–605
30. Chackarian AA, Oldham ER, Murphy EE, Schimtz J, Pflanz S, Kastelein RA et al (2007) IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 179:2551–2555
31. Luo H, Higuchi K, Matsumoto K, Mori M (2013) An interleukin-33 gene polymorphism is a modifier for eosinophilia in rats. Genes Immun 14(3):192–197
32. Martín JE, Bossini-Castillo L, Martín J (2012) Unraveling the genetic component of systemic sclerosis. Hum Genet 131(7):1023–1037
33. Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales R et al (2010) Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 42(5):426–429
34. Allanore Y, Saad M, Dieudé P, Avouac J, Distler JH, Amouyel P et al (2011) Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet 7(7):e1002091
35. Gorlova O, Martin JE, Rueda B, Koeleman BP, Ying J, Teruel M et al (2011) Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet 7(7):e1002178